RHHBY Overview
Upcoming Projects (RHHBY)
-
A Second View: Discussing the APL-2 Phase 2 FILLY Data in Geographic Atrophy (GA) and IVERIC bio’s Zimura.
Tickers: APLS, RHHBY, ISEE
Execute By: May 29, 2020
Executed Projects (RHHBY)
-
A Second Opinion: Discussing the DLBCL landscape and emerging therapies/mechanisms including: Polivy, Tafasitimab, bi-specifics, and CAR-Ts.
Tickers: MOR, RHHBY
Executed On: May 13, 2020 at 11:00 AM EDT -
Discussing the DLBCL landscape and emerging therapies/mechanisms including: Polivy, Tafasitimab, bi-specifics, and CAR-Ts.
Tickers: MOR, RHHBY
Executed On: May 01, 2020 at 03:30 PM EDT -
Discussing the APL-2 Phase 2 FILLY Data in Geographic Atrophy (GA) and IVERIC bio’s Zimura.
Tickers: APLS, RHHBY, ISEE
Executed On: Mar 27, 2020 at 11:00 AM EDT -
A Community Oncologist's View: Discussing the current treatment landscape for AML (Vyxeos, Idhifa/Tibsovo) and where Venclexta could fit in after recently gaining FDA accelerated approval
Tickers: JAZZ, ABBV, RHHBY, AGIO
Executed On: Dec 13, 2018 at 04:30 PM EST -
Discussing the current treatment landscape for AML (Vyxeos, Idhifa/Tibsovo) and where Venclexta could fit in after recently gaining FDA accelerated approval
Tickers: JAZZ, RHHBY, ABBV, AGIO
Executed On: Dec 05, 2018 at 11:00 AM EST -
Discussing Puma Bio's NERLYNX (neratinib) for HER2-positive Breast Cancer with a prescribing physician in the community setting
Tickers: PBYI, RHHBY, RO.SW
Executed On: Aug 29, 2018 at 03:30 PM EDT -
Discussing developments in Diabetic Eye Disease from the Bascom Palmer Angiogenesis Meeting
Tickers: REGN, NVS, RHHBY, ARPO
Executed On: Feb 26, 2018 at 10:30 AM EST -
Discussing NERLYNX (neratinib) for HER2-positive Breast Cancer Post FDA Approval
Tickers: PBYI, RHHBY, RO.SW
Executed On: Jan 18, 2018 at 09:00 AM EST -
Exploring Clearside's (CLSD) Zurpata for the treatment of Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO)
Tickers: CLSD, REGN, RHHBY
Executed On: Aug 28, 2017 at 04:30 PM EDT -
Understanding the mechanism of action and public data for MN-166 (ibudilast) in Progressive MS in preparation for the Phase 2 interim analysis in the 4Q of 2016.
Tickers: MNOV, BIIB, RHHBY, MedDay Pharmaceuticals
Executed On: Dec 12, 2016 at 11:30 AM EST -
A discussion of the OHR management's analysis of its failed Phase 2 IMPACT study for OHR-102 and subsequent newly designed Phase 3 study
Tickers: OHRP, REGN, RHHBY
Executed On: Dec 29, 2015 at 02:00 PM EST
Free Project
Expired Projects (RHHBY)
-
Electroporation Expert Interview: An Overview and its Pharmaceutical Potential
Tickers: INO, PFE, RHHBY, ROLL
Execute By: Nov 02, 2016
Included with Membership -
Evaluating the Multiple Sclerosis Market After AbbVie (ABBV) and Biogen (BIIB) Receive CHMP Support for EU Approval of Zinbryta
Tickers: ABBV, BIIB, TEVA, NVS, SNY, MedDay Pharmaceuticals, RHHBY
Execute By: May 23, 2016 -
Evaluating the Market Potential of Hua Medicine's HMS5552 in Type II Diabetes Ahead of Mid-Year Phase II Readout. Does the drug have potential to derail the success of major players in the space?
Tickers: HUA MEDICINE, ABT, AZN, NVS, NVO, MRK, SNY, GSK, Lupin Pharmaceuticals, RHHBY
Execute By: May 11, 2016
Upcoming & Overdue Catalysts (RHHBY)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (RHHBY)
-
Phase 2/3 data of RG7916 in Spinal Muscular Atrophy (SMA) to be presented at AAN May 7, 2019 1pm.
Tickers: PTCT, RHHBY
Occurred on: May 07, 2019 -
Celgene Expected to Complete Four Phase 3 Trials of ABRAXANE in Different Indications in 2017
Tickers: CELG, RHHBY
Occurred on: Jan 19, 2018 -
Roche Expands Atezolizumab Cancer Immunology Portfolio - Eleven Phase 1b Readouts expected in 2016
Ticker: RHHBY
Occurred on: Jun 03, 2017 -
Phase 3 LAVOLTA III Study Readout of Lebrikizumab For Severe Asthma Expected mid 2017
Ticker: RHHBY
Occurred on: May 19, 2017 -
Roche's (RHHBY) Tecentriq Approved by FDA for Advanced Bladder Cancer
Ticker: RHHBY
Occurred on: Apr 18, 2017 -
Alecensa (alectinib) Phase 3 ALEX Study Results Expected mid-2017 - Roche Seeking Approval in Japan
Ticker: RHHBY
Occurred on: Apr 10, 2017 -
Roche's (RHHBY) Rituxan Designated a Breakthrough Therapy by FDA for Pemphigus Vulgaris, a Rare Autoimmune Skin Disorder
Ticker: RHHBY
Occurred on: Mar 24, 2017 -
Roche (RHHBY) Phase 3 APHINITY Results Expected in Q1 2017 Evaluating Perjeta in Adjuvant Breast Cancer
Ticker: RHHBY
Occurred on: Mar 02, 2017 -
FDA approves Lucentis (ranibizumab injection) for myopic choroidal neovascularisation
Ticker: RHHBY
Occurred on: Jan 06, 2017 -
Roche (RHHBY) Launches DISCOVERY 5-Plex Procedure for Ventana System
Ticker: RHHBY
Occurred on: Nov 21, 2016 -
Roche (RHHBY) Initiates Two Phase 3 Studies Evaluating Tecentriq + Cotellic + Zelboraf in Patients with Advanced Melanoma
Ticker: RHHBY
Occurred on: Nov 07, 2016 -
FDA Accepts Biologics License Application For Subcutaneous Formulation Of Rituximab
Tickers: HALO, RHHBY
Occurred on: Nov 03, 2016 -
FDA Grants Priority Review to Atezolizumab - Biologics License Application Date set for September 12, 2016
Ticker: RHHBY
Occurred on: Oct 19, 2016 -
Roche's (RHHBY) Lucentis Prefilled Syringe Approved by FDA
Tickers: RHHBY, Genentech
Occurred on: Oct 14, 2016 -
Roche's (RHHBY) Lucentis sBLA Granted Priority Review by FDA for Treatment of Myopic Choroidal Neovascularization
Ticker: RHHBY
Occurred on: Oct 11, 2016 -
FDA grants breakthrough therapy designation for Roche’s (RHHBY) Actemra/RoActemra in giant cell arteritis, a form of vasculitis
Ticker: RHHBY
Occurred on: Oct 05, 2016 -
Anti-Cancer Agent “Xeloda”, Obtained Approval for Additional Indication of “Adjuvant Chemotherapy for Rectal Cancer”
Ticker: RHHBY
Occurred on: Aug 26, 2016 -
Roche’s emicizumab continued to show promising safety and efficacy profile in long-term study in people with severe haemophilia A
Ticker: RHHBY
Occurred on: Jul 28, 2016 -
Organovo and Roche Researchers Publish Data Demonstrating Superiority of 3D Bioprinted Human Liver Tissues in Assessing Drug-Induced Toxicity
Tickers: ONVO, RHHBY
Occurred on: Jul 11, 2016 -
FDA Approves Genentech’s Xolair (omalizumab) for Allergic Asthma in Children
Ticker: RHHBY
Occurred on: Jul 07, 2016 -
Roche Plans to File for Marketing Authorization and Submit Data to Global Regulatory Authorities for Ocrelizumab
Ticker: RHHBY
Occurred on: Jun 28, 2016 -
Roche’s Gazyvaro approved in Europe in combination with bendamustine for people with previously treated follicular lymphoma
Ticker: RHHBY
Occurred on: Jun 16, 2016 -
Genentech’s Cancer Immunotherapy Tecentriq (atezolizumab) Shrank Tumors in People with Previously Untreated Advanced Bladder Cancer
Ticker: RHHBY
Occurred on: Jun 05, 2016 -
Phase III Study Shows Genentech’s Actemra (tocilizumab) Maintained Steroid-Free Remission in People with Giant Cell Arteritis (GCA)
Ticker: RHHBY
Occurred on: Jun 05, 2016 -
Anti-Cancer Agent “Avastin” Obtained Approval for Additional Indication of Advanced or Recurrent Cervical Cancer
Ticker: RHHBY
Occurred on: May 23, 2016 -
FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer
Ticker: RHHBY
Occurred on: Apr 11, 2016 -
Roche to initiate testing for Zika virus at U.S. Blood Centres under FDA Investigational New Drug Application protocol
Ticker: RHHBY
Occurred on: Mar 31, 2016 -
Roche Releases Data on 2 Identical Phase 3 Studies of Lebrikizumab for the Treatment of Severe Asthma
Ticker: RHHBY
Occurred on: Feb 29, 2016 -
FDA approves Roche’s Gazyva (obinutuzumab) for certain people with previously treated follicular lymphoma
Ticker: RHHBY
Occurred on: Feb 29, 2016 -
Roche's Ocrelizumab Granted Breakthrough Therapy Designation by FDA
Ticker: RHHBY
Occurred on: Feb 17, 2016 -
With Cotellic + Zelboraf Combination Approved, Roche Looks to Develop Triple Combination Treatments With Atezolizumab
Ticker: RHHBY
Occurred on: Jan 28, 2016 -
FDA grants Priority Review for venetoclax NDA
Ticker: RHHBY
Occurred on: Jan 12, 2016 -
Tensha Therapeutics To Be Acquired By Roche
Ticker: RHHBY
Occurred on: Jan 11, 2016 -
Roche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer
Ticker: RHHBY
Occurred on: Jan 08, 2016
Strategic Initiatives (RHHBY)
-
Roche (RHHBY) buys cancer-focused oncology-specific electronic health record software developer Flatiron Health
Ticker: RHHBY
Announcement Date: Feb 15, 2018 -
Roche (RHHBY) Agrees to Acquire Eye Drug Maker ForSight VISION4
Ticker: RHHBY
Announcement Date: Jan 10, 2017 -
Roche (RHHBY) and Bristol-Myers Squibb (BMY) Announce Decrease in Cancer Drug Prices for Access to Britain's National Health Service (NHS)
Tickers: BMY, RHHBY
Announcement Date: Nov 17, 2016 -
Roche (RHHBY) and Halozyme (HALO) Sign Collaboration Agreement to Evaluate PEGPH20 and Tecentriq in Eight Types of Tumors
Tickers: HALO, RHHBY
Announcement Date: Nov 10, 2016 -
Novogen (NVGN) Licenses GDC-0084 for Gioblastoma from Genentech (RHBBY)
Tickers: RHHBY, NVGN, Genentech
Announcement Date: Oct 31, 2016 -
Eleven Biotherapeutics Announces Signing of Exclusive License Agreement
Tickers: EBIO, RHHBY, SESN
Announcement Date: Jun 13, 2016 -
Lilly and Roche Diagnostics to Collaborate on Alzheimer's Disease Adjunct Diagnostic Tool
Tickers: LLY, RHHBY
Announcement Date: Jan 27, 2016 -
Catalent Biologics Announces Research Collaboration With Roche On SMARTag Technology
Tickers: CTLT, RHHBY
Announcement Date: Jan 13, 2016
